RxDoctor Payments Data

Leslie Shepard, NP

Family · Conyers, GANPI 1629658075

Payments from drug & device makers

$3,939in general payments, 2019–2025

Across 96 payments — averaging $41.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Nevro Corp.$977
  • Collegium Pharmaceutical, Inc.$341
  • Curonix LLC$231
  • Biotronik NRO, Inc.$208
  • Globus Medical$166
  • plus $643 from 17 others

What the payments were for

  • Travel & lodging$66017%
  • Food & beverage$2,75070%
  • Education$52813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,939 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$7,558
Medicare patients
40
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl54$46,166
RelistorMethylnaltrexone Bromide16$44,179
ZtlidoLidocaine72$32,420
MovantikNaloxegol Oxalate64$27,103
LinzessLinaclotide25$13,051
Piroxicam19$10,833
Calcipotriene33$10,358
SymproicNaldemedine Tosylate15$6,693
Buprenorphine16$3,789
Gabapentin316$3,602
Lidocaine40$2,070
Tramadol Hcl99$1,788
Duloxetine Hcl96$1,787
Diclofenac Sodium115$1,642
Tizanidine Hcl185$1,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$341$46,16654 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$77$44,17916 claims
Scilex Pharmaceuticals Inc.Ztlido$56$32,42072 claims
AbbVieLinzess$58$13,05125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Conyers

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →